Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SANA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- 32.7% Withhold Vote For Director Hans E. Bishop (new) — Elevated opposition suggests stockholder dissatisfaction with Bishop's board service, warranting attention to governance concerns.
Sana Biotechnology elects three directors; Bishop faces 33% withhold vote
Filed June 5, 2026 · Period ending June 4, 2026 · ~1 min read
Key Changes
-
medium
Hans E. Bishop re-elected to Class II board seat despite 32.7% withhold vote (57.1M shares withheld vs. 117.5M for), signaling notable stockholder concern about his continued service through 2029.
Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR → -
low
Robert Nelsen and Alise S. Reicin re-elected with strong support (91.9% and 85.8% respectively), receiving 160.4M and 149.9M votes for their three-year terms.
Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR → -
low
Ernst & Young ratified as auditor for fiscal 2026 with 99.4% approval (203.9M for, 831K against).
Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR →
Summary
Sana Biotechnology's 2026 annual meeting produced a split outcome on board composition. While all three Class II director nominees won re-election to three-year terms, Hans E. Bishop faced significant stockholder pushback with 57.1 million shares withheld (32.7% of votes cast), compared to 117.5 million in support.
This level of opposition is unusual for an uncontested director election and suggests meaningful stockholder concerns about his continued board service through 2029. The company has not disclosed the specific drivers of this dissent. In contrast, fellow Class II directors Robert Nelsen and Alise S.
Reicin sailed through with 91.9% and 85.8% support respectively, indicating the concern is specific to Bishop rather than a broader governance protest. The auditor ratification passed routinely with 99.4% approval. Investors should watch for any board response to the Bishop vote result, such as enhanced stockholder engagement or governance changes, particularly given the three-year term ahead.
Section-by-Section Diff
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Sana Biotechnology held its 2026 annual meeting, electing three Class II directors and ratifying Ernst & Young as auditor for fiscal 2026.
Added in current filing · verify on EDGAR →
Nominees | For | Withheld | Broker Non-Votes Hans E. Bishop 117,452,573 | 57,148,432 | 30,606,441 | Robert Nelsen | 160,384,193 | 14,216,812 | 30,606,441 Alise S. Reicin, M.D. 149,865,546 | 24,735,459 | 30,606,441
Stockholders elected all three Class II director nominees to three-year terms expiring in 2029. Hans E. Bishop received 67.3% support (117,452,573 for vs. 57,148,432 withheld), Robert Nelsen received 91.9% support (160,384,193 for vs. 14,216,812 withheld), and Alise S. Reicin received 85.8% support (149,865,546 for vs. 24,735,459 withheld). The elevated withhold votes for Bishop (32.7%) indicate notable stockholder concern about his continued service on the board.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
For | Against | Abstain | 203,932,500 | 831,419 | 443,527
Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026. The proposal passed with 99.4% support (203,932,500 for, 831,419 against, 443,527 abstentions), reflecting routine approval of the auditor selection.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 21, 2026 · How we verify